TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Amplia Therapeutics ( (AU:ATX) ) is now available.
Amplia Therapeutics has announced its financial report for the half year ending September 2025, highlighting significant progress in its clinical trials. The company’s lead drug, narmafotinib, has shown promising results in the ACCENT trial for advanced pancreatic cancer, achieving a confirmed response rate of 33%, which is superior to existing treatments. A new trial, AMPLICITY, has also commenced, further exploring narmafotinib’s efficacy in combination with FOLFIRINOX.
The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.11 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company targets fibrotic cancers such as pancreatic and ovarian cancer, as well as chronic diseases like idiopathic pulmonary fibrosis.
Average Trading Volume: 1,483,624
Technical Sentiment Signal: Hold
Current Market Cap: A$61.57M
For a thorough assessment of ATX stock, go to TipRanks’ Stock Analysis page.